The company offers a low‑cost wearable device with a saliva test strip that detects D‑serine levels, an enzyme marker linked to NMDA receptor activity, to predict early risk of brain‑related diseases such as stroke and Alzheimer’s.
Funding
Funding not disclosed
Founders
Product
Problem
Early detection of brain‑related diseases such as ischemic stroke and Alzheimer’s disease is limited because current diagnostics rely on invasive procedures or expensive imaging, delaying preventive interventions.
Solution
Shaddiagnostics offers a low‑cost wearable device paired with a saliva test strip that measures D‑serine levels, an enzyme marker linked to NMDA receptor activity in the brain. The test strip contains electronic ink that reacts to D‑serine in saliva, providing a quantitative readout without needles or blood draws. Results are generated at home and can be transmitted to clinicians, giving an early warning signal of elevated risk for stroke or Alzheimer’s disease. By enabling frequent, non‑invasive monitoring, the technology supports preventive care decisions before clinical symptoms manifest.
Target Audience
Primary users are individuals at risk for stroke or Alzheimer’s disease and healthcare providers seeking a simple, early‑warning screening tool for brain health.
Features
- Wearable form factor with integrated saliva test strip for at‑home use
- Electronic ink sensor that detects D‑serine concentrations linked to NMDA receptor function
- Needle‑free, non‑invasive sampling requiring only a brief placement of the strip in the mouth
- Low‑cost design aimed at broad accessibility and frequent monitoring
- Data output compatible with clinician review for early risk assessment of stroke and Alzheimer’s disease